Drug Profile
CN 128
Alternative Names: CN-128Latest Information Update: 03 Jan 2023
Price :
$50
*
At a glance
- Originator Hangzhou Zede Pharmaceutical Technology
- Class Antianaemics; Heterocyclic acids; Pyridones; Small molecules; Thiazoles
- Mechanism of Action Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Iron overload; Thalassaemia
- Preclinical Aplastic anaemia; Myelodysplastic syndromes; Parkinson's disease
Most Recent Events
- 03 Jan 2023 CN 128 is still in phase II clinical trials in Iron overload and Thalassaemia (In adolescents, In adults) in China (PO)
- 02 Jun 2022 Hangzhou Zede Pharmaceutical Technology initiates a phase IIb trial for Thalassaemia and Iron overload (In adults, In adolescents) in China (PO, Tablet) (NCT05355766)
- 02 May 2022 Hangzhou Zede Pharmaceutical Technology plans a phase IIb trial for Thalassaemia and Iron overload (In adults, In adolescents) in China (PO, Tablet) (NCT05355766)